Investment Rating - The investment rating for JD Health (06618) is maintained as "Buy" [2] Core Insights - JD Health reported a significant revenue growth of 26.3% year-on-year, reaching 73.44 billion RMB in 2025, which exceeded market expectations by 3.1% [7] - The company's Non-IFRS operating profit margin and net profit margin reached historical highs, benefiting from optimized revenue structure and improved operational efficiency [7] - The company continues to see strong growth in its core e-commerce business, with pharmaceutical and health product sales increasing by 24.8% to 60.9 billion RMB [7] - The active user base reached 217.7 million, a 19% increase year-on-year, with over 100 new drugs launched on the platform in 2025 [7] - JD Health is actively exploring AI applications across various scenarios, enhancing platform conversion efficiency [7] Financial Forecast - Revenue projections for 2026-2028 are estimated at 86.26 billion RMB, 98.96 billion RMB, and 111.65 billion RMB respectively, with corresponding net profits of 6.57 billion RMB, 7.63 billion RMB, and 8.72 billion RMB [6][8] - The company is expected to maintain a robust growth trajectory, with a net profit growth rate of 5.6% in 2026 and 16.84% in 2027 [6] - The earnings per share (EPS) is projected to increase from 1.70 RMB in 2025 to 2.40 RMB in 2028 [6] Key Financial Metrics - The company reported a cash reserve of 69.5 billion RMB at the end of 2025 [7] - The return on equity (ROE) is expected to improve from 8.95% in 2025 to 9.76% in 2028 [6] - The price-to-earnings (P/E) ratio is projected to decrease from 28.73 in 2025 to 17.72 in 2028, indicating potential valuation improvement [6]

Summary of Conference Call Records Industry Overview - The pharmaceutical marketing industry is shifting from traffic competition to value provision, emphasizing full-process empowerment for patients, including chronic disease and health management. Digital marketing investment is expected to grow significantly, reaching 24% by 2025 [1][5][14]. Key Insights and Arguments - **Unique Position of GO in Pharmaceuticals**: GO has a unique position in the pharmaceutical field, where AI models can provide professional consultation but cannot replace the prescription authority of doctors. Pharmaceutical companies may utilize AI models for advertising, with some already experimenting with this approach [1][4]. - **Digital Marketing Metrics**: Advertisers focus on GMV (Gross Merchandise Volume), sales, and ROI (Return on Investment), while brand owners emphasize supply chain value and patient lifecycle value, shifting from CPC (Cost Per Click) to the value of each lead [1][6]. - **Efficiency Improvement through Digitalization**: Medical platforms enhance management efficiency for doctors and patients by providing educational resources, patient management functions, and innovative online payment methods, as well as supporting home services [1][7][8]. - **Major Players**: Key players in digital marketing include large internet healthcare platforms like JD Health and Alibaba Health, which focus on supply chain value and comprehensive patient management rather than just product sales [1][5]. Additional Important Content - **Growth of Digital Marketing**: The scale of digital marketing is expanding, with growth rates projected at 18.7% in 2023, 24% in 2024, and 19%-20% in 2025. The share of GO is expected to increase from 22% in 2023 to 41% in 2025 [1][5]. - **JD Health's New Drug Launch Platform**: JD Health aims to create a new drug launch platform supported by AI laboratories, with new drug launches expected to account for 30% of the overall budget and a gross profit margin of about 10% to 12% [1][17]. - **Impact of New Products**: The recent launch of new products by JD Health and Alibaba Health aims to better serve doctors and hospitals, enhancing data systematization and patient management [1][11][12]. - **Future Growth Trends**: Digital marketing is expected to maintain a strong growth trend over the next three years, with annual growth rates projected to exceed 30% due to changes in operational models that deepen the integration of pharmaceutical companies and major platforms [1][14]. - **Compliance in Content Generation**: JD Health employs a dynamic monitoring system to ensure compliance in generating healthcare content, utilizing blockchain technology to meet regulatory requirements [1][20]. - **Challenges in AI Development**: The development of AI technology in internet healthcare faces challenges, including strict data regulations and the need for real-time updates to AI models due to evolving medical research and treatment methods [1][21]. Competitive Landscape - **Competition with Other Platforms**: JD Health competes with platforms like Doubao and Qianwen, which rely on open interfaces and lack real-time supply chain data. JD Health's advantage lies in its comprehensive data and services [1][18]. - **Flow Doubling Strategy**: JD Health's flow doubling plan has significantly increased user engagement, with average user time rising from 2.1 minutes to 8 minutes and conversion rates improving by 2.5 times [1][22][23]. - **Digital Marketing Profit Margins**: JD Health's digital marketing gross profit margin typically ranges from 50% to 60%, although not all services achieve this level of profitability [1][15][16]. Conclusion - The pharmaceutical digital marketing landscape is evolving rapidly, with significant investments in technology and innovative strategies to enhance patient engagement and operational efficiency. JD Health and Alibaba Health are at the forefront of this transformation, leveraging AI and digital platforms to capture market share and improve service delivery.